Does the media prefer ZBIO or MYGN?

In the previous week, Zenas BioPharma had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 5 mentions for Zenas BioPharma and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat Zenas BioPharma's score of 0.68 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MYGN or INVA more profitable?

Innoviva has a net margin of 119.89% compared to Myriad Genetics' net margin of -48.24%. Innoviva's return on equity of 33.33% beat Myriad Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -48.24% -8.51% -4.48% Innoviva 119.89% 33.33% 22.67%

Does the media favor MYGN or INVA?

In the previous week, Myriad Genetics and Myriad Genetics both had 3 articles in the media. Innoviva's average media sentiment score of 1.37 beat Myriad Genetics' score of 1.08 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, NVAX or MYGN?

Novavax has higher revenue and earnings than Myriad Genetics. Novavax is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.27 $440.30M -$0.58 N/A Myriad Genetics $824.50M 0.69 -$365.90M -$4.30 N/A

Is NVAX or MYGN more profitable?

Novavax has a net margin of -14.73% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Myriad Genetics -48.24% -8.51% -4.48%

Does the media refer more to NVAX or MYGN?

In the previous week, Novavax had 20 more articles in the media than Myriad Genetics. MarketBeat recorded 23 mentions for Novavax and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat Novavax's score of 0.89 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MYGN or MNKD more profitable?

MannKind has a net margin of -6.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -48.24% -8.51% -4.48% MannKind -6.63% -11.21% -3.92%

Does the media favor MYGN or MNKD?

In the previous week, MannKind had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 5 mentions for MannKind and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat MannKind's score of 0.55 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OPK or MYGN?

In the previous week, OPKO Health had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 5 mentions for OPKO Health and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat OPKO Health's score of -0.03 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Myriad Genetics (MYGN) Competitors

$6.02 +0.16 (+2.71%)

As of 01:01 PM Eastern

Compare

MYGN vs. ZBIO, INVA, NVAX, MNKD, and OPK

Should you buy Myriad Genetics stock or one of its competitors? MarketBeat compares Myriad Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Myriad Genetics include Zenas BioPharma (ZBIO), Innoviva (INVA), Novavax (NVAX), MannKind (MNKD), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry.

How does Myriad Genetics compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Zenas BioPharma presently has a consensus price target of $44.29, suggesting a potential upside of 58.16%. Myriad Genetics has a consensus price target of $6.50, suggesting a potential upside of 7.99%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Zenas BioPharma is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Myriad Genetics has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	176.76	-$377.74M	-$8.47	N/A
Myriad Genetics	$824.50M	0.69	-$365.90M	-$4.30	N/A

99.0% of Myriad Genetics shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Zenas BioPharma has a net margin of 0.00% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Myriad Genetics	-48.24%	-8.51%	-4.48%

Zenas BioPharma has a beta of -0.96, indicating that its share price is 196% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

In the previous week, Zenas BioPharma had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 5 mentions for Zenas BioPharma and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat Zenas BioPharma's score of 0.68 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Myriad Genetics beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Innoviva?

Myriad Genetics (NASDAQ:MYGN) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Myriad Genetics has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Innoviva has a net margin of 119.89% compared to Myriad Genetics' net margin of -48.24%. Innoviva's return on equity of 33.33% beat Myriad Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
Innoviva	119.89%	33.33%	22.67%

Myriad Genetics currently has a consensus price target of $6.50, indicating a potential upside of 7.99%. Innoviva has a consensus price target of $36.20, indicating a potential upside of 65.33%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Myriad Genetics and Myriad Genetics both had 3 articles in the media. Innoviva's average media sentiment score of 1.37 beat Myriad Genetics' score of 1.08 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.69	-$365.90M	-$4.30	N/A
Innoviva	$411.33M	3.93	$271.17M	$6.01	3.64

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 2.0% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Innoviva beats Myriad Genetics on 13 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to Novavax?

Novavax (NASDAQ:NVAX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Novavax presently has a consensus price target of $13.00, indicating a potential upside of 49.72%. Myriad Genetics has a consensus price target of $6.50, indicating a potential upside of 7.99%. Given Novavax's stronger consensus rating and higher possible upside, analysts plainly believe Novavax is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Novavax has higher revenue and earnings than Myriad Genetics. Novavax is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.27	$440.30M	-$0.58	N/A
Myriad Genetics	$824.50M	0.69	-$365.90M	-$4.30	N/A

Novavax has a net margin of -14.73% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Myriad Genetics	-48.24%	-8.51%	-4.48%

Novavax has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Novavax had 20 more articles in the media than Myriad Genetics. MarketBeat recorded 23 mentions for Novavax and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat Novavax's score of 0.89 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novavax beats Myriad Genetics on 12 of the 17 factors compared between the two stocks.

How does Myriad Genetics compare to MannKind?

Myriad Genetics (NASDAQ:MYGN) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Myriad Genetics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market. Comparatively, MannKind has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

MannKind has a net margin of -6.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
MannKind	-6.63%	-11.21%	-3.92%

In the previous week, MannKind had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 5 mentions for MannKind and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat MannKind's score of 0.55 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has lower revenue, but higher earnings than Myriad Genetics. MannKind is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.69	-$365.90M	-$4.30	N/A
MannKind	$348.97M	3.51	$5.86M	-$0.07	N/A

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Myriad Genetics presently has a consensus price target of $6.50, indicating a potential upside of 7.99%. MannKind has a consensus price target of $8.97, indicating a potential upside of 126.20%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

MannKind beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

OPKO Health has higher earnings, but lower revenue than Myriad Genetics. OPKO Health is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.52	-$225.68M	-$0.27	N/A
Myriad Genetics	$824.50M	0.69	-$365.90M	-$4.30	N/A

64.6% of OPKO Health shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 44.7% of OPKO Health shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

OPKO Health has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

OPKO Health has a net margin of -36.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Myriad Genetics	-48.24%	-8.51%	-4.48%

In the previous week, OPKO Health had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 5 mentions for OPKO Health and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.08 beat OPKO Health's score of -0.03 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OPKO Health presently has a consensus target price of $1.55, suggesting a potential upside of 26.53%. Myriad Genetics has a consensus target price of $6.50, suggesting a potential upside of 7.99%. Given OPKO Health's higher possible upside, equities analysts clearly believe OPKO Health is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Myriad Genetics beats OPKO Health on 9 of the 16 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYGN vs. The Competition

Export

Metric	Myriad Genetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$566.98M	$3.65B	$6.75B	$12.53B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.40	21.17	26.99	24.42
Price / Sales	0.69	316.30	586.45	117.94
Price / Cash	1.55	61.98	29.22	49.36
Price / Book	1.52	8.59	10.87	6.36
Net Income	-$365.90M	$23.83M	$3.58B	$330.77M
7 Day Performance	2.71%	-2.87%	-1.89%	-0.78%
1 Month Performance	39.01%	7.03%	3.52%	-0.16%
1 Year Performance	15.31%	49.82%	26.88%	20.18%

Myriad Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYGN Myriad Genetics	2.0668 of 5 stars	$6.02 +2.7%	$6.50 +8.0%	+9.7%	$566.98M	$824.50M	N/A	2,700	Positive News
ZBIO Zenas BioPharma	3.5189 of 5 stars	$26.45 -2.9%	$44.29 +67.4%	+149.4%	$1.72B	$10M	N/A	N/A
INVA Innoviva	3.7608 of 5 stars	$21.82 -2.2%	$36.20 +65.9%	+18.3%	$1.65B	$411.33M	3.63	100
NVAX Novavax	2.2132 of 5 stars	$9.35 -4.0%	$13.00 +39.0%	+30.3%	$1.60B	$1.12B	N/A	1,990
MNKD MannKind	3.6077 of 5 stars	$4.27 -5.5%	$8.97 +110.0%	+7.2%	$1.40B	$348.97M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYGN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Competitors

MYGN vs. ZBIO, INVA, NVAX, MNKD, and OPK

How does Myriad Genetics compare to Zenas BioPharma?

Summary

How does Myriad Genetics compare to Innoviva?

Summary

How does Myriad Genetics compare to Novavax?

Summary

How does Myriad Genetics compare to MannKind?

Summary

How does Myriad Genetics compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Competitors

MYGN vs. ZBIO, INVA, NVAX, MNKD, and OPK

How does Myriad Genetics compare to Zenas BioPharma?

Do analysts prefer ZBIO or MYGN?

Which has preferable valuation and earnings, ZBIO or MYGN?

Do insiders & institutionals hold more shares of ZBIO or MYGN?

Is ZBIO or MYGN more profitable?

Which has more volatility & risk, ZBIO or MYGN?

Does the media prefer ZBIO or MYGN?

Summary

How does Myriad Genetics compare to Innoviva?

Which has more volatility and risk, MYGN or INVA?

Is MYGN or INVA more profitable?

Do analysts recommend MYGN or INVA?

Does the media favor MYGN or INVA?

Which has higher valuation and earnings, MYGN or INVA?

Do insiders & institutionals have more ownership in MYGN or INVA?

Summary

How does Myriad Genetics compare to Novavax?

Do analysts rate NVAX or MYGN?

Which has preferable valuation and earnings, NVAX or MYGN?

Is NVAX or MYGN more profitable?

Which has more volatility & risk, NVAX or MYGN?

Do institutionals and insiders believe in NVAX or MYGN?

Does the media refer more to NVAX or MYGN?

Summary

How does Myriad Genetics compare to MannKind?

Which has more risk & volatility, MYGN or MNKD?

Is MYGN or MNKD more profitable?

Does the media favor MYGN or MNKD?

Which has preferable earnings and valuation, MYGN or MNKD?

Do insiders & institutionals have more ownership in MYGN or MNKD?

Do analysts rate MYGN or MNKD?

Summary

How does Myriad Genetics compare to OPKO Health?

Which has better earnings and valuation, OPK or MYGN?

Do insiders and institutionals hold more shares of OPK or MYGN?

Which has more risk and volatility, OPK or MYGN?

Is OPK or MYGN more profitable?

Does the media refer more to OPK or MYGN?

Do analysts rate OPK or MYGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools